Associação Entre Níveis de Vitamina D e Esquizofrenia
Evidências Epidemiológicas e Pré-Clínicas
DOI:
https://doi.org/10.34024/rnc.2013.v21.8170Palavras-chave:
Vitamina D, Sistema Nervoso Central, Deficiência de Vitaminas, EsquizofreniaResumo
Objetivo. Realizar uma revisão da literatura sobre a associação entre baixos níveis de vitamina D e desenvolvimento de esquizofrenia. Método. Foi realizada uma revisão bibliográfica baseada em estudos experimentais pré-clínicos, observacionais e de revisão, através das bases de dados MEDLINE, LILACS e BIREME, utilizando os descritores vitamina D, sistema nervoso central, deficiência de vitaminas e esquizofrenia, nos idiomas português, inglês e espanhol. Os critérios de inclusão compreendiam abordagem direta do tema e disponibilidade eletrônica. Resultados. Foram encontrados 35 artigos, sendo selecionados 13 artigos, de acordo com os critérios de inclusão. Conclusão. O estudo verificou a existência de uma associação entre baixos níveis de vitamina D e desenvolvimento de esquizofrenia, embora não se saiba ao certo como essa associação é estabelecida, devido à carência de estudos experimentais na área. É necessária a realização de estudos mais aprofundados, uma vez que baixos níveis de vitamina D são comuns e prevalentes na população.
Downloads
Métricas
Referências
Stahl SM. Psicofarmacologia - Base neurocientífica e aplicações práticas. 2ed. São Paulo: MEDSI Editora médica e científica, 2002, 617p.
DeLisi LE. The significance of age of onset for schizophrenia. Schizophr Bull 1992;18:209-15. http://dx.doi.org/10.1093/schbul/18.2.209
Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9. http://dx.doi.org/10.1001/archpsyc.1987.01800190080012
Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009;35:528-48. http://dx.doi.org/10.1093/schbul/sbn187
McGrath JJ, Susser ES. New directions in the epidemiology of schizophrenia. Med J Aust 2009;190:S7-9.
WHO Schizophrenia (endereço na Internet). Suíça: World Health Organization. (atualizado em: 30/2012; citado em: 12/2012). Disponível em: http://www.who.int/mental_health/management/schizophrenia/en/
Masana M, Bortolozzi A, Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol 2011;14:53-68. http://dx.doi.org/10.1017/S1461145710000908
Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49:487-99. http://dx.doi.org/10.1016/S0006-3223(01)01067-8
Boos HB, Cahn W, van Haren NE, Derks EM, Brouwer RM, Schnack HG, et al. Focal and global brain measurements in siblings of patients with schizophrenia. Schizophr Bull 2012;38:814-25. http://dx.doi.org/10.1093/schbul/sbq147
Kesby JP, Eyles DW, Burne TH, McGrath JJ. The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol 2011;347:121-7. http://dx.doi.org/10.1016/j.mce.2011.05.014
Dealberto MJ. Why are immigrants at increased risk for psychosis? Vitamin D insufficiency, epigenetic mechanisms, or both? Med Hypotheses 2007;68:259-67.
Stumpf WE, O’Brien LP. 1,25(OH)2 vitamin D3 sites of action in the brain. An autoradiographic study. Histochemistry 1987;87:393-406. http://dx.doi.org/10.1007/BF00496810
McGrath J, Feron F, Eyles D, Mackay-Sim A. Vitamin D: the neglected neurosteroid? Trends Neurosci 2001; 10:570-2.
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888-94. http://dx.doi.org/10.1210/jc.86.2.888
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution ofthe vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30. http://dx.doi.org/10.1016/j.jchemneu.2004.08.006
Harms LR, Burne TH, Eyles DW, McGrath JJ. Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab 2011;25:657-69. http://dx.doi.org/10.1016/j.beem.2011.05.009
McGrath JJ, Burne TH, Feron F, Mackay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull 2010;36:1073-8. http://dx.doi.org/10.1093/schbul/sbq101
Kesby JP, Burne TH, McGrath JJ, Eyles DW. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia. Biol Psychiatry 2006;60:591-6. http://dx.doi.org/10.1016/j.biopsych.2006.02.033
McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case- -control study. Arch Gen Psychiatry 2010;67:889-94. http://dx.doi.org/10.1001/archgenpsychiatry.2010.110
Kesby JP, Cui X, O’Loan J, McGrath JJ, Burne TH, Eyles DW. Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology (Berl) 2010;208:159-68. http://dx.doi.org/10.1007/s00213-009-1717-y
Feron F, Burne TH, Brown J, Smith E, McGrath JJ, Mackay-Sim A, et al. Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res Bull 2005;65:141-8. http://dx.doi.org/10.1016/j.brainresbull.2004.12.007
McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 1999;40:173-7.
Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin D3 and brain development. Neuroscience 2003;118:641-53. http://dx.doi.org/10.1016/S0306-4522(03)00040-X
Kesby JP, Cui X, Ko P, McGrath JJ, Burne TH, Eyles DW. Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neurosci Lett 2009;461:155-8. http://dx.doi.org/10.1016/j.neulet.2009.05.070
Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. http://dx.doi.org/10.1056/NEJMra070553
McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008;22:982-1001.
Wood SJ, Pantelis C, Velakoulis D, Yucel M, Fornito A, McGorry PD. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr Bull 2008;34:322-9. http://dx.doi.org/10.1093/schbul/sbm149
Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52. http://dx.doi.org/10.1002/syn.890010203
Tekes K, Gyenge M, Folyovich A, Csaba G. Influence of neonatal vitamin A or vitamin D treatment on the concentration of biogenic amines and their metabolites in the adult rat brain. Horm Metab Res 2009;41:277-80. http://dx.doi.org/10.1055/s-0028-1103287
Baksi SN, Hughes MJ. Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. Brain Res 1982;242:387-90. http://dx.doi.org/10.1016/0006-8993(82)90331-6
Pardridge WM, Sakiyama R, Coty WA. Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. J Neurochem 1985;44:1138-41. http://dx.doi.org/10.1111/j.1471-4159.1985.tb08735.x
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97. http://dx.doi.org/10.1016/S0006-3223(01)01303-8
Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122:593-624.
Burke RE. Ontogenic cell death in the nigrostriatal system. Cell Tissue Res 2004;318:63-72. http://dx.doi.org/10.1007/s00441-004-0908-4
Kholodilov N, Yarygina O, Oo TF, Zhang H, Sulzer D, Dauer W, et al. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets.
J Neurosci 2004;24:3136-46. http://dx.doi.org/10.1523/JNEUROSCI.4506-03.2004
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2013-09-30
Português
English
Español
